t
MedPal AI plc announced on April 8, 2026, the release of an updated research note by Optimo Research and a new investor interview with CEO Jason Drummond. Optimo Research Ltd updated its coverage of MedPal AI on April 2. In the investor interview, CEO Jason Drummond stated that over 200,000 prescription orders have been processed since launch.
REACH non-regulatory announcement
8 April 2026
MedPal AI plc
(the "Company" or "MedPal AI")
Updated Research Note
MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to announce the release of an updated research note by Optimo Research, alongside a new investor interview with CEO Jason Drummond.
On Thursday 2 April, Optimo Research Ltd updated its coverage of MedPal AI, covering the significant progress made by the company since its IPO in August 2025.
The research can be downloaded on the Optimo Research website here:
https://www.optimocapital.co.uk/library-2
In addition, in a new investor interview CEO Jason Drummond has shared how a combination of AI-driven diagnostics, clinician access, and robotic dispensing has enabled rapid growth, with over 200,000 prescription orders processed since launch. The interview can be accessed on the ADVFN website here:
For further information please visit www.medpalplc.com or contact:
|
MedPal AI plc Jason Drummond, Chief Executive Officer
|
Via Square1 Consulting |
|
Clear Capital Markets Limited Bob Roberts
|
+44 (0) 20 3869 6080 |
|
Square1 Consulting David Bick |
+44 (0) 20 7929 5599 +44 (0) 7831 381201 |
About MedPal AI
MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.
Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.
MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms.
The Company's LEI is 984500EDP8B0A14CBA61.
Follow us on social media:
X: @MedPalPlc
LinkedIn: MedPal AI plc
About Reach announcements
This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only/non-regulatory news releases Into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or any other regulation would be disseminated as an RNS regulatory announcement and not on Reach.